[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583412":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":36,"collaborators":7,"id":38,"slug":7,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Otsuka Pharmaceutical Co., Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Brexpiprazole (Rexulti)","In general, for adults, start with taking 0.5 mg of brexpirazole at a time, once a day. Then the dose will be increased with an interval of at least one week to 1 mg at a time, once a day. If you have no problem with tolerability and do not show an adequate response, the dose may be increased to 2 mg at a time, once a day, but the increase should be made at intervals of at least one week.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd","CONTACT","+81-6-6943-7722","komaniwa.satoshi@otsuka.jp",[20],{"facility":21,"status":22,"city":23,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Pharmacovigilance Department","RECRUITING","Osaka","540-0021","Japan","JP",{"type":28,"coordinates":29},"Point",[30,31],135.50107,34.69379,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":17,"phoneExt":7,"email":18},"Study Director",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100583412",false,"NCT06875986","REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically\u002FVerbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and\u002For Outbursts Associated With Dementia Due to Alzheimer's Disease)","Inclusion Criteria:\n\n* Patients diagnosed with Alzheimer's disease\n\nExclusion Criteria:\n\n\\-","ALL","15 Years",{"count":46,"type":47},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.",[51],"Alzheimer Disease","2025-06-27",{"date":54,"type":55},"2025-07-02","ACTUAL",{"date":57,"type":55},"2025-04-17",{"date":59,"type":47},"2028-09-23",{"name":5,"class":6},1]